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See related article on page 513. Lung volume reduction surgery (LVRS) has resulted in perhaps themost dynamic controversy within cardiothoracic surgery in recentyears. Initial publications reported compelling improvements in pul-monary function and resulted in rapid dissemination of the procedurethroughout the United States and the world. The rationale for theenthusiasm was legitimate given the lack of alternative therapies for
patients with severe end-stage emphysema. No medical therapy was able to improve
pulmonary function or reverse the inexorable decline of breathless patients with
emphysema. Only a very small subset of these patients were candidates for the
surgical interventions of bullectomy or lung transplantation. Therefore, the oppor-
tunity to improve function and quality of life with a new surgical procedure inspired
the hopes of desperate patients and their physicians. LVRS was easily the most
exciting and innovative addition to general thoracic surgery since the first successful
lung transplant procedure 20 years ago.
Parallel to the rapid clinical dissemination of LVRS, controversy emerged
regarding the procedure’s efficacy, long-term outcomes, selection criteria, and costs.
Many clinicians raised legitimate questions regarding the validity of the early
clinical reports, citing small patient numbers, incomplete follow-up, selection bias,
and survivorship or follow-up bias as multiple factors confounding the interpretation
of clinical outcomes from LVRS. Critics pointed at early publications that docu-
mented a high surgical mortality, prolonged mechanical ventilation, and prolonged
hospital stays in some patients.1 Medicare claims data revealed a 1-year mortality
after LVRS of 23%, with uncertainty of whether this denoted the expected mortality
of a progressive natural history of emphysema, or whether poor results were
under-represented because of centers that performed LVRS but did not publish their
outcomes.2 These criticisms reflected the normal debate and evolution that are a
natural order of dynamic and evolving medical care. Until LVRS, new procedures
and interventions have primarily been evaluated by an evolutionary process of
procedure refinement, observational studies, and occasionally randomized con-
trolled trials. Randomized trials have generally been performed late within the
process of procedure development, well after most interested clinicians believed that
the majority of indications and outcomes were fairly well known.
LVRS has been developed in a new era—a time when evidence-based medicine
is emphasized over the trial and error inherent in the development of new medical
therapies. Insurers, and particularly Medicare, have become increasingly involved
with medical decisions as well. Some of this is justifiable to prevent health care
dollars from being squandered on frivolous therapies. However, since no clear
criteria for Medicare coverage exist, decisions regarding reimbursement for a new
procedure such as LVRS can easily appear arbitrary. Critics of the Medicare
decision to withdraw reimbursement for LVRS believe that this decision moves
uncomfortably close to government decisions of appropriate medical therapy for
individual patients at best, or the unethical withholding of a promising therapy in an
effort to control medical expenditures at worst. Bowing to public and legislative
pressure, Medicare agreed to fund the historic National Emphysema Treatment Trial
(NETT) as a pioneering collaboration between the National Institutes of Health
(NIH) and Medicare in evaluating a new surgical procedure. The NETT developed
as a large multi-institutional prospective randomized trial, comparing LVRS to
maximal medical therapy in patients with severe emphysema.
Debate has continued to swirl around the NETT. Many LVRS proponents believe
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that sufficient case-control evidence exists to allow cover-
age in highly selected patients. In fact, some argued that
requiring Medicare patients to enroll within the NETT to
have a 50% chance of being randomized to LVRS consisted
of coercion to participate in a randomized controlled trial.
On the other hand, many applauded the innovative collab-
oration between Medicare and the NIH. The NETT assured
rigorous evaluation of LVRS before it became widely ap-
plied and clinical biases limited the ability to conduct a
randomized controlled trial. The NETT hoped to protect
potential patients who may have experienced unnecessary
morbidity or mortality as indications and outcomes gradu-
ally evolved in the fragmented process of single-institution
observational studies.
It appears that both of these arguments have significant
validity. As our patients’ advocates, physicians bristle at the
notion of a potentially beneficial treatment being denied for
one of their patients. On the other hand, as clinical scien-
tists, we wish to scientifically validate new treatment with as
much precision as possible in an effort to avoid the possible
harm of inappropriate use. This dilemma between individ-
ual patient advocacy and scientific validation of efficacy is
not easily resolved and has led to a huge debate about the
appropriateness of Medicare’s coverage policy and support
of a randomized trial. Clearly, LVRS is being subjected to
a higher standard of validation than virtually any other
medical or surgical treatment in the past. It is possible that
political and economic considerations may be driving the
heightened attention to LVRS. However, this cynical view
rejects the notion that early and rigorous scrutiny of a new
medical therapy may actually allow us to apply or discard
that therapy more quickly and with more confidence, max-
imizing the benefit and minimizing the morbidity for the
largest number of patients.
No matter how one views the political or economic
events surrounding LVRS, the work and beliefs of the
individual investigators and the NETT investigators are
remarkably consistent, with less variation than might be
expected between proponents of LVRS or proponents of the
recently completed randomized trial of LVRS (NETT).
When the polemic is set aside, it is easy to see that both
groups of clinicians and investigators are complementary,
working in the same direction, and both refining the role of
LVRS in clinical practice. In this month’s issue of the
Journal, the article by Ciccone and her colleagues3 at Wash-
ington University is the most important article to date in
refining long-term outcomes after LVRS. Each of the suc-
cessive publications from Cooper’s group at Washington
University has substantially increased our understanding of
LVRS—outlining the pilot experience,4 examining interme-
diate-term outcomes in a larger cohort,5 and comparing
outcomes between matched patients receiving or denied
LVRS.6 Ciccone’s article adds substantially to these previ-
ous reports, now with 250 patients followed up for a mean
interval of almost 5 years and a minimal follow-up of 18
months. Although most other reports have been flawed by
missing data, which can easily obscure negative outcomes,
the Washington University group has achieved remarkable
and complete follow-up that tempers criticism about the
validity of their outstanding results. This article, as well as
the consistent scientific and rigorous evaluation of the
Washington University clinical outcomes, displays the
highest quality of single-institution case-controlled or ob-
servational studies. The authors have done everything
right—prospective collection of data, consistent indications
and techniques, sizable patient cohort, objective outcome
variables, and rigorous efforts to maintain complete follow-
up. Despite these strengths, this experience is still limited by
its study design—problems with selection bias, survivorship
bias, and statistical bias, as well as the difficulty of predict-
ing reproducibility in other surgeons and other centers.
Selection bias is a confounding factor in any nonrandom-
ized clinical trial, with known or unanticipated variables
influencing the outcome in unpredictable and unsuspected
ways. Selection of patients for LVRS has been based on
vague criteria that limit reproducibility between centers.
The Washington University group has learned to apply their
selection criteria wisely, with good results. However, it is
not clear whether this should define the selection of future
patients considering LVRS. Perhaps with more stringent
criteria, results could be further improved and morbidity
lessened. Or perhaps the criteria should be broader, provid-
ing access to LVRS for more patients who would be ex-
cluded from LVRS benefits by immature selection defini-
tions.
Survivorship bias is a corollary of follow-up bias. In-
complete follow-up in nonrandomized studies confounds
interpretation of the outcomes because lack of follow-up is
rarely random—poor follow-up usually over-represented by
patients with poor outcomes. However, survivorship bias
occurs when patient death prevents the continued consider-
ation of that patient’s outcome after surgery. In the case of
LVRS, it is highly likely that death occurs most commonly
in those patients with a poor result after surgery and that
subsequent data are measured only in those patients who are
more robust or who have benefited from surgery. This can
significantly influence the interpretation of results when a
large percentage of patients have died over the follow-up
interval. Although it is likely that this mortality rate may be
due to the natural history of emphysema, it is hard to know
the detrimental or beneficial impact of LVRS on mortality
in the absence of a randomized study. Unfortunately, the
progressive distortion of long-term functional results by
mortality tempers the enthusiasm we can have for long-term
results in a nonrandomized study.
Statistical bias occurs when mean data are presented for
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case-controlled studies that compare individual patient data
before and after treatment. In the case of LVRS, patients
consent to surgery with the hope for a clinically significant
improvement in lung function and/or symptoms. Most data
after LVRS provide the mean improvement in forced expi-
ratory volume in 1 second (FEV1), 6-minute walk, or dys-
pnea score and may also give a percentage of patients
“improved” after LVRS. However, it is impossible to cal-
culate from these data how many patients actually achieved
a clinically significant improvement after surgery. Numeri-
cal or subjective, but negligible, improvement is calculated
as a benefit but may be clinically insignificant to the indi-
vidual patient. A minority of patients having a very large
benefit can also skew the mean. Given the expectation of
LVRS for patients with emphysema, a more precise mea-
surement of benefit would probably be to set a clinically
meaningful threshold that could then be objectively mea-
sured, such as a defined improvement in FEV1, 6-minute
walk, dyspnea scale, or maximum work. The percentage of
patients achieving this outcome would then be defined as
improved after LVRS and provide a better measure of how
many patients are truly benefiting within our current selec-
tion criteria and surgical technique.
Finally, although single-institution studies provide a nec-
essary pilot experience for a new surgical procedure, the
true value of the procedure cannot be extrapolated from a
single-institution experience. A number of institutional, se-
lection, and individual factors may allow a hospital to
achieve exceptional results in an area where they have
experience, interests, and specialization. These results are
needed to consider broader application of the surgical pro-
cedure. However, for LVRS to make a meaningful impact
on patients with emphysema, multi-institutional studies are
necessary to confirm the applicability of the operation and
the results within definable selection criteria and across a
spectrum of institutions and surgeons.
The results reported in this issue of the Journal by
Ciccone and her colleagues are an important advance in our
knowledge of LVRS. They confirm the apparent benefit of
LVRS over several years in a select group of patients at a
center with a high level of expertise in pulmonary medicine
and thoracic surgery. This experience does not obviate the
need for a randomized trial. Indeed, the single-institution
case-controlled trial and a randomized trial are complemen-
tary: the first providing the experience on which to base a
randomized trial; the latter providing the most precise and
unbiased evidence of efficacy and allowing broader selec-
tion criteria to be examined and refined. Single-institution
studies will then be an important follow-up to a randomized
trial to confirm, refine, or repudiate randomized trial find-
ings. The NETT will publish its results this spring and will
complement the work that Cooper and his colleagues have
started with their LVRS experience. The individual contri-
butions by the large number of investigators pioneering
LVRS development, along with the collective contributions
of the NETT investigators, have propelled the knowledge
surrounding LVRS far beyond that of any similar new
technology or procedure in its adolescence.
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